Home › Funds › Soros Fund Management › ALNY
Soros Fund Management position in ALNY
ALNYLAM PHARMACEUTICALS INC · Health Care
Soros Fund Management reported holding 99,000,000 shares of ALNY (ALNYLAM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$90.7M, representing 1.28% of its reported portfolio and ranking #16 among its reported holdings. Soros Fund Management has disclosed ALNY holdings in 7 of the last 51 reported quarters, going back to Q1 2014.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Soros Fund Management's ALNY position evolved
Soros Fund Management first disclosed a stake in ALNY in Q1 2014 at 3,092 shares (US$208K). The position peaked in Q3 2026 at 99,000,000 shares, worth US$90.7M. Across 7 filings, Soros Fund Management held the position steady without any share-count change. The most recent filing (Q3 2026) shows 99,000,000 shares valued at US$90.7M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2014 | 3.09K | $208.00K | New |
| Q4 2015 | 6.00K | $565.00K | New |
| Q2 2017 | 7.00K | $558.00K | New |
| Q2 2019 | 40.00K | $2.90M | New |
| Q1 2025 | 60.00K | $16.20M | New |
| Q3 2025 | 4.29K | $1.96M | New |
| Q3 2026 | 99.00M | $90.69M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ALNY and 13F data
ALNY (ALNYLAM PHARMACEUTICALS INC) is a Health Care company. 30 other funds we track also report a position in ALNY — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.70B), Baillie Gifford & Co (US$1.36B), Orbis Allan Gray Ltd (US$598.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ALNY
- T. Rowe Price Investment Management, Inc. 5.64M sh · $1.70B · Q2 2026
- Baillie Gifford & Co 5.49M sh · $1.36B · Q3 2026
- Orbis Allan Gray Ltd 1.99M sh · $598.27M · Q2 2026
- Two Sigma Investments 1.88M sh · $564.71M · Q2 2026
- TWO SIGMA ADVISERS, LP 1.13M sh · $450.36M · Q4 2025
- Deep Track Capital, LP 825.00K sh · $248.35M · Q2 2026
More on Soros Fund Management
FAQ
How long has Soros Fund Management held ALNY?
Soros Fund Management has disclosed ALNY holdings in 7 of the last 51 reported quarters, going back to Q1 2014.
What is Soros Fund Management's current position in ALNY?
As of Q3 2026, Soros Fund Management holds 99.00M shares of ALNY (ALNYLAM PHARMACEUTICALS INC), valued at $90.69M, representing 1.28% of its reported portfolio and ranking #16.
Has Soros Fund Management been buying or selling ALNY?
In the latest 13F filing (Q3 2026), Soros Fund Management newly opened its position in ALNY. The position peaked in Q3 2026 at 99.00M shares.
Which other funds hold ALNY?
Other major institutional holders of ALNY include T. Rowe Price Investment Management, Inc., Baillie Gifford & Co, Orbis Allan Gray Ltd, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.